What does this research mean for the field?

Cefiderocol resistance in KPC-producing Pseudomonas aeruginosa evolves through a bifurcated response, characterized by multi-scale regulatory shifts in iron uptake and efflux during clinical adaptation, and acute genetic transitions such as KPC-33 mutations and siderophore receptor disruptions under laboratory induction. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to understand the mechanisms and evolution of cefiderocol resistance in KPC-producing strains of Pseudomonas aeruginosa.

July 26, 2026Communications BiologyOpen Access

Mechanistic and evolutionary determinants of cefiderocol resistance in KPC-producing Pseudomonas aeruginosa

View Full Paper

Ask AI

Bookmark

Authors

WWWenhao Wu XLX M Li LZLongjie Zhou

Discussion

Member takes

Overview

Randomized trial analyzes cefiderocol resistance in KPC-producing Pseudomonas aeruginosa, suggesting implications for treatment strategies.

Key Points

This research aims to understand the mechanisms and evolution of cefiderocol resistance in KPC-producing strains of Pseudomonas aeruginosa.
Analyzed 25 clinical KPC-variant-producing Pseudomonas aeruginosa strains and laboratory-induced resistant strains using whole genome sequencing (WGS), RNA sequencing (RNA-seq), RT-qPCR, and metabolomics.
Conducted QM/MM simulations to assess catalytic site dynamics and resistance mechanisms.
Identified that 25 clinical isolates were highly resistant to ceftazidime-avibactam (25/25), but largely susceptible to cefiderocol (22/25).
FDC-induced strains acquired mutations and disruptions in siderophore receptors, optimizing KPC-33 catalytic dynamics and increasing bacterial resistance.
Observed a bifurcated adaptation response linked to antibiotic pressure, with regulatory shifts in iron uptake for clinical isolates and acute mutations for lab-induced strains.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/6a65a306d3aea3239cd76467 https://doi.org/10.1038/s42003-026-10726-7

View Full Paper

Ask AI

Bookmark

July 26, 2026Communications BiologyOpen Access

Mechanistic and evolutionary determinants of cefiderocol resistance in KPC-producing Pseudomonas aeruginosa

View Full Paper

Ask AI

Bookmark

Authors

WWWenhao Wu XLX M Li LZLongjie Zhou

Discussion

Member takes

Overview

Randomized trial analyzes cefiderocol resistance in KPC-producing Pseudomonas aeruginosa, suggesting implications for treatment strategies.

Key Points

This research aims to understand the mechanisms and evolution of cefiderocol resistance in KPC-producing strains of Pseudomonas aeruginosa.
Analyzed 25 clinical KPC-variant-producing Pseudomonas aeruginosa strains and laboratory-induced resistant strains using whole genome sequencing (WGS), RNA sequencing (RNA-seq), RT-qPCR, and metabolomics.
Conducted QM/MM simulations to assess catalytic site dynamics and resistance mechanisms.
Identified that 25 clinical isolates were highly resistant to ceftazidime-avibactam (25/25), but largely susceptible to cefiderocol (22/25).
FDC-induced strains acquired mutations and disruptions in siderophore receptors, optimizing KPC-33 catalytic dynamics and increasing bacterial resistance.
Observed a bifurcated adaptation response linked to antibiotic pressure, with regulatory shifts in iron uptake for clinical isolates and acute mutations for lab-induced strains.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/6a65a306d3aea3239cd76467 https://doi.org/10.1038/s42003-026-10726-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark